Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Zacks
More News
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Zacks
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Zacks
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Zacks
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
Zacks
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
Zacks
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
Zacks
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
Zacks
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.
Zacks
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.